MetaCap

Ascendis Pharma A/S Stock Forecast

NASDAQ: ASNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

252.73-3.23 (-1.26%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ASND analyst consensus

Consensus (21 analysts)

strong_buy

Avg. price target

$315.78+24.95%

  • Strong buy 5
  • Buy 15
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $273.12High $354.86

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

What analysts say

According to 21 Wall Street analysts covering Ascendis Pharma A/S (2026-11-16), 20 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $315.78, with a high estimate of $354.86 and a low estimate of $273.12. The average target implies upside of 24.9% from the current price of $252.73.

The spread between the highest and lowest targets is 29.9%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ASND.

Summary generated from market data by MetaCap's automated system. Methodology

Rating distribution

Ascendis Pharma A/S analyst rating distribution
RatingAnalystsShare
Strong buy524%
Buy1571%
Hold15%
Sell00%
Strong sell00%

Ratings as of 2026-11-16.

Price target scenarios

Price targets versus the current price
TargetPricevs. current
Low target$273.12+8.07%
Average target$315.78+24.95%
High target$354.86+40.41%

How analysts view Ascendis Pharma A/S's peers

Peer analyst targets
CompanyConsensusPriceAvg. targetImplied move
BBIOstrong_buy76.03$107.00+40.73%
JAZZstrong_buy230.26$297.50+29.20%
ALNYbuy143.82$289.22+101.10%
ELANbuy25.74$31.00+20.44%
RDYbuy14.89$14.92+0.20%
BMRNbuy60.41$90.30+49.48%

Related